Royalty Pharma plc
NASDAQRoyalty Pharma enters the final stretch of August with an awkward split: options positioning remains at its most call-heavy reading of the past year while the executives running the company have been selling into the strength. The options signal established last week has not faded. The put/call ratio dropped further to 0.14 on Friday — 3.3 standard deviations below its 20-day mean…
RPRX put-call ratio crashes to 0.15, a 4-sigma decline from its 20-day mean of 0.21, signaling extreme bullish sentiment in options markets.
Snapshot as of 20 Sept 2026
Royalty Pharma enters the final stretch of August with an awkward split: options positioning remains at its most call-heavy reading of the past year while the executives running the company have been selling into the…
Royalty Pharma is heading into the second half of August with a quietly unusual setup — options positioning has swung to its most bullish extreme of the past year, even as the stock puts in a steady 3.2% week and the…
Royalty Pharma heads into its Q1 2026 earnings call on May 8 with the stock at a one-year high — and its own CFO cashing out along the way. The most striking data point heading into the print is not in the options…
Royalty Pharma headed into its Q1 2026 print with options traders already positioned for upside — and the results gave them reason to hold that view. The earnings story is split down the middle. Adjusted EPS came in at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RPRX — free to start on ORTEX.
Sign up for free →Open RPRX on ORTEX